比美吉珠单抗双靶抑制IL-17A/IL-17F对中轴型脊柱关节炎炎症与结构病变的影响
基于BE MOBILE 1(nr-axSpA)和2(r-axSpA)两项3期研究及其开放标签扩展,评估比美吉珠单抗双抑制IL-17A和IL-17F对骶髂关节和脊柱炎症及结构损伤的影响。第52周,比美吉珠单抗组MRI炎症显著降低,骶髂关节侵蚀评分下降、填充增加,关节强直变化极小;至第104周,mNY和mSASSS平均较基线变化分别为0.03和0.3。
要点
- 比美吉珠单抗治疗52周显著降低nr-axSpA和r-axSpA骶髂关节及脊柱MRI炎症。
- 52周时骶髂关节侵蚀评分下降、填充评分增加,关节强直变化极小。
- 治疗至104周,影像学结构进展极小(mNY平均变化0.03,mSASSS平均变化0.3)。
核心结论
- 比美吉珠单抗双抑制IL-17A和IL-17F可显著降低axSpA骶髂关节和脊柱MRI炎症,并逐渐减少骶髂关节侵蚀,影像学进展极小。
研究设计与样本
- BE MOBILE 1(nr-axSpA)和2(r-axSpA)为3期研究,含16周双盲安慰剂对照期和36周维持期,第16周起全部接受比美吉珠单抗160 mg皮下注射每4周一次。
- 第52周患者可进入开放标签扩展继续比美吉珠单抗治疗。
- MRI亚研究在基线、第16周和第52周采用SPARCC骶髂关节和Berlin脊柱炎症评分及SPARCC骶髂关节结构评分评估。
- 基线及第104周有X线的患者评估骶髂关节结构损伤(mNY标准,nr-axSpA)和脊柱结构损伤(mSASSS,r-axSpA)。
- 报告观察病例数据。
主要发现
- 第52周,比美吉珠单抗随机组SPARCC骶髂关节评分平均较基线变化:nr-axSpA -7.6,r-axSpA -5.1。
- 第52周,Berlin脊柱评分平均较基线变化:nr-axSpA -0.5,r-axSpA -2.5。
- 第52周,骶髂关节侵蚀评分平均较基线变化:nr-axSpA -1.8,r-axSpA -1.8。
- 第52周,填充评分平均较基线变化:nr-axSpA 0.9,r-axSpA 0.6;脂肪病变评分平均较基线变化:nr-axSpA 0.7,r-axSpA 0.5。
- 第52周,关节强直评分平均较基线变化:nr-axSpA 0.0,r-axSpA 0.2。
关键数值与推荐
- 比美吉珠单抗给药方案:皮下160 mg每4周一次。
- 第104周,nr-axSpA患者mNY平均较基线变化为0.03。
- 第104周,r-axSpA患者mSASSS平均较基线变化为0.3。
临床怎么用
- 对于axSpA患者,比美吉珠单抗双靶抑制IL-17A和IL-17F可改善骶髂关节和脊柱MRI炎症,并可能延缓结构损伤进展。
- 治疗期间可通过MRI炎症评分和X线结构评分监测骶髂关节和脊柱病变变化。
局限性
- 报告为观察病例数据。
- MRI亚研究和影像学评估仅限于部分患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non-radiographic axSpA [nr-axSpA]) and 2 (radiographic axSpA [r-axSpA]) and their open-label extension (OLE). METHODS: BE MOBILE 1 and 2 comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, patients could enter the OLE to continue bimekizumab. MRI scans were evaluated by treatment arm at baseline and weeks 16 and 52 in BE MOBILE 1 and 2 MRI substudies using Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ and Berlin spine inflammation scores, and SPARCC SIJ structural score (SSS; erosion, backfill, fat lesions, and ankylosis). In patients with baseline and week 104 radiographs, structural damage was assessed in the SIJ (modified New York [mNY] criteria; nr-axSpA) and spine (modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS]; r-axSpA). Observed case data are reported. RESULTS: At week 52, bimekizumab-randomized patients had substantially reduced inflammation (mean change from baseline [CfB]: SPARCC SIJ, nr-axSpA -7.6; r-axSpA -5.1; Berlin spine, nr-axSpA -0.5; r-axSpA -2.5), decreased erosion scores (nr-axSpA -1.8; r-axSpA -1.8), increased backfill (nr-axSpA 0.9; r-axSpA 0.6) and fat lesion scores (nr-axSpA 0.7; r-axSpA 0.5), and minimal changes in ankylosis (nr-axSpA 0.0; r-axSpA 0.2). With bimekizumab treatment to week 104, radiographs showed mean CfB of 0.03 in mNY (nr-axSpA) and mSASSS of 0.3 (r-axSpA). CONCLUSION: Dual inhibition of IL-17A and IL-17F with bimekizumab led to substantial reductions in MRI SIJ/spine inflammation, gradual decreases in SIJ erosion, and minimal radiographic progression in the SIJ/spine in patients with axSpA.
引用
- Maksymowych WP, Ramiro S, Poddubnyy D, et al. Impact of Dual Interleukin-17A and Interleukin-17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open-Label Extension. Arthritis Rheumatol. 2026. PMID: 42740449. doi:10.1002/art.70336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。